Knowledge Ecology International conducted a review of contracts entered into by the US government concerning COVID-19-related treatments, diagnostics, vaccines, and other countermeasure-related technologies, regarding reference pricing clauses in the agreements. Of the 104 contracts reviewed, it is difficult to say… Continue Reading
KEI has created a public listserve to discuss vaccine manufacturing scale up. (link) February 19, 2021: Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines – 19. KEI has gathered data regarding vaccine manufacturing capacity in countries worldwide,… Continue Reading
United States of America Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted… Continue Reading
At a May 28,2020 press briefing organized by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), pharma CEOs and the IFPMA DG commented on the WHO proposal for a global pool for rights in technologies for the diagnosis, prevention… Continue Reading
From AstraZeneca’s 20-F, section on Risk Factors, for fiscal year ended December 31, 2012. Number of words in Item 1A: 8621 Compulsory licensing of patents: 45 3D. Risk Factors The information (including tabular data) set forth or referenced under the… Continue Reading
September 3, 2011 From KEI staff review of Wikileaks cables (/wikileaks) On May 14, 2008, The US Embassy in Warsaw sent a cable that discussed additions to the list of pharmaceutical products reimbursed by the government. A few highlights from… Continue Reading